Masashi Kato

Masashi Kato

Auto-generated profile, based on publicly available information

Masashi Kato

Department of Cardiology Mitsubishi Kyoto Hospital Kyoto Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2020 in Circulation Journal
Verified
Journal Article
Open access
PDF file
YTYasuaki Takeji
Yasuaki Takeji
TTTomohiko Taniguchi
Tomohiko Taniguchi
TMTakeshi Morimoto
Takeshi Morimoto
NSNaritatsu Saito
Naritatsu Saito
KAKenji Ando
Kenji Ando
OIon behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
on behalf of the CURRENT AS Registry Investigators and K-TAVI Registry Investigators
Background:There are no data comparing transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) outcomes in real clinical practice in Japan. Methods and Results:We combined 2 independent registries, the K-TAVI Registry (a 6-center prospective registry of consecutive patients who underwent TAVI) and the CURRENT AS Registry (a large, 27-center registry of 3,815 consecutive patients with severe aortic stenosis [AS]). In the K-TAVI Registry, 338 patients underwent TAVI with SAPIEN XT balloon-expandable valves from October 2013 to January 2016, whereas in the CURRENT AS Registry 237 patients with severe AS underwent SAVR from January 2003 to December 2011. Propensity score matching was conducted, with final cohort comprising 306 patients. The cumulative 2-year incidence of all-cause death and heart failure (HF) hospitalization did not differ significantly between the TAVI and SAVR groups (13.7% vs. 12.4% [P=0.81] and 7.9% vs 3.9% [P=0.13], respectively). After adjusting for residual confounders, there were no significant differences between the TAVI and SAVR groups in the risk for all-cause death (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.35–1.58; P=0.43) or HF hospitalization (HR 1.27; 95% CI 0.40–4.59; P=0.69). Conclusions:These findings from 2 independent Japanese registries suggest that the 2-year risk of all-cause mortality and HF does not differ significantly between TAVI and SAVR groups in real-world practice in Japan.

5 April 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TKTetsuma Kawaji
Tetsuma Kawaji
HOHisashi Ogawa
Hisashi Ogawa
YHYasuhiro Hamatani
Yasuhiro Hamatani
MKMasashi Kato
Masashi Kato
TYTakafumi Yokomatsu
Takafumi Yokomatsu
TIthe Fushimi AF Registry investigators
the Fushimi AF Registry investigators
Background: The clinical significance of fibrillatory wave on electrocardiography during atrial fibrillation (AF) is poorly understood. The aim of the current study was to explore the association of fine fibrillatory wave with heart failure (HF) in AF. Methods and Results: The current study enrolled 2442 patients with AF whose baseline ECG during AF rhythm was available from a community‐based prospective survey, the Fushimi AF Registry. The impact of fine fibrillatory wave, defined as the amplitude of fibrillatory waves <0.1 mV, on the primary composite HF end point (a composite of hospitalization attributable to HF or cardiac death) was examined. Fine fibrillatory wave was observed in 589 patients (24.1%). Patients with fine fibrillatory wave were older, and had a higher prevalence of sustained AF, preexisting HF, and larger left atrial diameter than those with coarse fibrillatory wave. During the median follow‐up duration of 5.9 years, the cumulative incidence of the primary composite HF end point was significantly higher in patients with fine fibrillatory wave than in those with coarse fibrillatory wave (5.3% versus 3.6% per patient‐year, log‐rank P <0.001). The higher risk associated with fine fibrillatory wave was consistent even for individual components of the primary composite HF end point. On multivariable analysis, fine fibrillatory wave became an independent predictor for the primary composite HF end point (hazard ratio, 1.31; 95% CI, 1.07–1.61; P =0.01). Conclusions: Compared with coarse fibrillatory wave, fine fibrillatory wave was more prevalent in patients with a larger left atrial diameter or those with sustained AF and was independently associated with a higher risk of HF events. Registration: URL: https://www.umin.ac.jp/ctr/ ; Unique identifier: UMIN000005834.

22 April 2022 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
TKTetsuma Kawaji
Tetsuma Kawaji
TATakanori Aizawa
Takanori Aizawa
SHShun Hojo
Shun Hojo
HYHidenori Yaku
Hidenori Yaku
KNKenji Nakatsuma
Kenji Nakatsuma
SMShinji Miki
Shinji Miki

5 May 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EYErika Yamamoto
Erika Yamamoto
TKTakao Kato
Takao Kato
HYHidenori Yaku
Hidenori Yaku
TMTakeshi Morimoto
Takeshi Morimoto
YIYasutaka Inuzuka
Yasutaka Inuzuka
TKTakeshi Kimura
Takeshi Kimura
Objective: The complex link between nutritional status, protein and lipid synthesis, and immunity plays an important prognostic role in patients with heart failure. However, the association between appetite loss at discharge and long-term outcome remains unclear. Methods: The Kyoto Congestive Heart Failure registry is a prospective cohort study that enrolled consecutive patients hospitalized for acute decompensated heart failure (ADHF) in Japan. We assessed 3528 patients alive at discharge, and for whom appetite and follow-up data were available. We compared one-year clinical outcomes in patients with and without appetite loss at discharge. Results: In the multivariable logistic regression analysis using 19 clinical and laboratory factors with P value < 0.1 by univariate analysis, BMI < 22 kg/m2 (odds ratio (OR): 1.57, 95% confidence interval (CI): 1.11–2.24, P = 0.01), CRP >1.0mg/dL (OR: 1.49, 95%CI: 1.04–2.14, P = 0.03), and presence of edema at discharge (OR: 4.30, 95%CI: 2.99–6.22, P<0.001) were associated with an increased risk of appetite loss at discharge, whereas ambulatory status (OR: 0.57, 95%CI: 0.39–0.83, P = 0.004) and the use of ACE-I/ARB (OR: 0.70, 95% CI: 0.50–0.98, P = 0.04) were related to a decreased risk in the presence of appetite loss. The cumulative 1-year incidence of all-cause death (primary outcome measure) was significantly higher in patients with appetite loss than in those without appetite loss (31.0% vs. 15.0%, P<0.001). The excess adjusted risk of appetite loss relative to no appetite loss remained significant for all-cause death (hazard ratio (HR): 1.63, 95%CI: 1.29–2.07, P<0.001). Conclusions: Loss of appetite at discharge was associated with worse 1-year mortality in patients with ADHF. Appetite is a simple, reliable, and useful subjective marker for risk stratification of patients with ADHF.

9 November 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TKTetsuma Kawaji
Tetsuma Kawaji
SSSatoshi Shizuta
Satoshi Shizuta
TATakanori Aizawa
Takanori Aizawa
SYShintaro Yamagami
Shintaro Yamagami
YTYasuaki Takeji
Yasuaki Takeji
TKTakeshi Kimura
Takeshi Kimura
Atrial fibrillation (AF) and renal failure coexist and interact. However, scarce data about association between renal function and clinical outcomes in patients undergoing catheter ablation for AF are available. We sought to evaluate long-term renal function and clinical outcomes after AF ablation. We enrolled 791 non-dialysis patients undergoing catheter ablation for AF, and evaluated the incidence of worsening renal function (WRF) after the procedure, defined as >30% decline in estimate glomerular filtration rate. Mean follow-up duration was 5.1±2.5 years. Five hundreds and twenty-six patients (66.5%) were free from recurrent atrial arrhythmias without any antiarrhythmic drugs at the time of final follow-up. Cumulative incidence of WRF was 13.2% at 5-year after procedure, which was significantly higher in patients with recurrent AF compared to those without (21.6% versus 8.7%, P<0.001). In the multivariable analysis, recurrent AF was an independent risk factor for WRF (adjusted hazard ratio [HR] 1.89, 95% confidence interval 1.27–2.81, P = 0.002), along with congestive heart failure, diabetes, and eGFR <60 ml/min/1.73m2 at baseline. Patients with WRF had significantly higher 5-year incidences of all-cause death, cardiovascular death, heart failure hospitalization, ischemic stroke, and major bleeding compared to those without WRF. After adjustment of baseline differences in the multivariate Cox model, the excessive risks of WRF for all-cause death and heart failure hospitalization remained significant (adjusted HR 3.46, P = 0.002; adjusted HR 3.67, P<0.001). In AF patients undergoing catheter ablation for AF, arrhythmia recurrence was associated with WRF during follow-up, which was a strong predictor of adverse clinical outcomes.

1 January 1994 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
TITakafumi Ichida
Takafumi Ichida
MKMasashi Kato
Masashi Kato
AHAkihito Hayakawa
Akihito Hayakawa
SIShinichi Ito
Shinichi Ito
SMShigeki Mori
Shigeki Mori
HAHitoshi Asakura
Hitoshi Asakura